Ziprasidone Treatment of Two Adolescents with Psychosis

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 1, 2004, Pages 137-142

  Meighen, Karen G ^a   Shelton, Heather M ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; DIPHENHYDRAMINE; FLUPHENAZINE; LYSERGIDE; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ANAMNESIS; ARTICLE; BRIEF PSYCHOTIC DISORDER; CASE REPORT; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISORIENTATION; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GAIT DISORDER; HALLUCINATION; HUMAN; LABORATORY TEST; MALE; MASKLIKE FASCIE; PHARMACEUTICAL CARE; PHYSICAL EXAMINATION; PSYCHOSIS; RIGIDITY; SIDE EFFECT; SPEECH DISORDER; SYMPTOM; TACHYCARDIA; TREATMENT OUTCOME;

ADOLESCENT; FEMALE; HUMANS; MALE; PIPERAZINES; PSYCHOTIC DISORDERS; THIAZOLES;

EID: 1942443018     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454604773840580     Document Type: Article

References (10)

1. Czekalla J, Kollack-Walker S, Beasley CM Jr: Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics. J Clin Psychiatry 62(Suppl 2):35-40, 2001.
2. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerabation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491-505, 1999.
3. Keck P Jr, Buffenstein A, Ferguson J, Feig J, Jaffe W, Harrigan EP, Morrissey MR: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology (Berl) 140:173-184, 1998.
4. McDougle CJ, Kem DL, Posey DJ: Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921-927, 2002.
5. Patel NC, Sierk P, Dorson PG, Crismon ML: Experience with ziprasidone. J Am Acad Child Adolesc Psychiatry 41:495, 2002.
6. Potenza MN, McDougle CJ: Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs 9:213-232, 1998.
7. Psychopharmacological Drugs Advisory Committee: FDA Background Document on Zeldox (PDAC 0700.M01). Rockville (Maryland), U.S. Food and Drug Administration, 2000.
8. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM: Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299, 2000.
9. Stigler KA, Potenza MN, McDougle CJ: Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 3:927-942, 2001.
10. Tandon R, Harrigan E, Zorn SH: Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential. Journal of Serotonin Research 4:159-177, 1997.